Anti-MerTK antibodies and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11897968-B2
Application number	US-202017118921-A
Country	US
Kind code	B2
Filing date	Dec 11, 2020
Priority date	Dec 13, 2019
Publication date	Feb 13, 2024
Grant date	Feb 13, 2024

Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MerTK polypeptide, e.g., a mammalian MerTK or human MerTK, and use of such compositions in treating an individual in need thereof.

First claim

What is claimed is:

1. An isolated antibody that binds to human MerTK, wherein the antibody comprises an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of:
(i) SEQ ID NOs: 75, 99, 125, 158, 187, and 207, respectively;
(ii) SEQ ID NOs: 76, 100, 126, 159, 187, and 208, respectively;
(iii) SEQ ID NOs: 77, 101, 127, 160, 188, and 209, respectively;
(iv) SEQ ID NOs: 75, 99, 128, 158, 187, and 210, respectively;
(v) SEQ ID NOs: 78, 102, 129, 161, 189, and 211, respectively;
(vi) SEQ ID NOs: 75, 103, 130, 158, 187, and 212, respectively;
(vii) SEQ ID NOs: 77, 101, 127, 162, 188, and 209, respectively;
(viii) SEQ ID NOs: 75, 99, 131, 163, 187, and 213, respectively;
(ix) SEQ ID NOs: 79, 104, 132, 164, 190, and 214, respectively;
(x) SEQ ID NOs: 80, 105, 133, 165, 191, and 215, respectively;
(xi) SEQ ID NOs: 81, 106, 134, 166, 192, and 216, respectively;
(xii) SEQ ID NOs: 82, 107, 135, 167, 193, and 217, respectively;
(xiii) SEQ ID NOs: 77, 108, 136, 167, 194, and 209, respectively;
(xiv) SEQ ID NOs: 75, 109, 137, 168, 187, and 218, respectively;
(xv) SEQ ID NOs: 83, 99, 138, 158, 187, and 210, respectively;
(xvi) SEQ ID NOs: 84, 99, 139, 169, 195, and 219, respectively;
(xvii) SEQ ID NOs: 85, 99, 140, 170, 196, and 220, respectively;
(xviii) SEQ ID NOs: 86, 99, 141, 171, 191, and 221, respectively;
(xix) SEQ ID NOs:87, 110, 142, 172, 197, and 222, respectively;
(xx) SEQ ID NOs: 88, 99, 143, 173, 191, and 223, respectively;
(xxi) SEQ ID NOs: 89, 111, 143, 173, 198, and 221, respectively;
(xxii) SEQ ID NOs: 90, 112, 144, 174, 199, and 224, respectively;
(xxiii) SEQ ID NOs: 91, 113, 145, 175, 200, and 225, respectively;
(xxiv) SEQ ID NOs: 90, 114, 146, 176, 201, and 226, respectively;
(xxv) SEQ ID NOs: 92, 115, 147, 177, 195, and 227, respectively;
(xxvi) SEQ ID NOs: 93, 116, 148, 178, 188, and 209, respectively;
(xxvii) SEQ ID NOs: 94, 117, 149, 179, 195, and 228, respectively;
(xxviii) SEQ ID NOs: 95, 118, 150, 180, 187, and 229, respectively;
(xxix) SEQ ID NOs: 95, 119, 151, 181, 187, and 208, respectively;
(xxx) SEQ ID NOs: 90, 120, 152, 182, 202, and 230, respectively;
(xxxi) SEQ ID NOs: 96, 118, 153, 183, 202, and 230, respectively;
(xxxii) SEQ ID NOs: 96, 121, 154, 181, 187, and 210, respectively;
(xxxiii) SEQ ID NOs: 90, 122, 155, 184, 203, and 231, respectively;
(xxxiv) SEQ ID NOs: 90, 122, 155, 184, 203, and 231, respectively;
(xxxv) SEQ ID NOs:97, 123, 156, 185, 204, and 232, respectively;
(xxxvi) SEQ ID NOs: 98, 124, 157, 186, 205, and 233, respectively;
(xxxvii) SEQ ID NOs: 83, 329, 334, 158, 187, and 210, respectively;
(xxxviii) SEQ ID NOs: 83, 330, 138, 158, 187, and 210, respectively;
(xxxix) SEQ ID NOs: 83, 329, 138, 340, 187, and 210, respectively;
(xl) SEQ ID NOs: 83, 329, 138, 341, 187, and 210, respectively;
(xli) SEQ ID NOs: 83, 329, 335, 341, 187, and 210, respectively;
(xlii) SEQ ID NOs: 83, 331, 138, 341, 187, and 210, respectively;
(xliii) SEQ ID NOs: 83, 329, 138, 342, 187, and 210, respectively;
(xliv) SEQ ID NOs: 83, 329, 336, 341, 187, and 210, respectively;
(xlv) SEQ ID NOs: 83, 329, 337, 343, 187, and 210, respectively;
(xlvi) SEQ ID NOs: 83, 332, 338, 341, 187, and 210, respectively;
(xlvii) SEQ ID NOs: 83, 333, 334, 158, 187, and 210, respectively;
(xlviii) SEQ ID NOs: 83, 332, 336, 341, 187, and 210, respectively;
(xlix) SEQ ID NOs: 83, 329, 339, 344, 187, and 210, respectively;
(l) SEQ ID NOs: 83, 329, 138, 158, 187, and 210, respectively;
(li) SEQ ID NOs: 84, 329, 139, 169, 195, and 219, respectively;
(lii) SEQ ID NOs: 84, 99, 139, 345, 195, and 219, respectively;
(liii) SEQ ID NOs: 346, 348, 355, 341, 187, and 360, respectively;
(liv) SEQ ID NOs: 95, 119, 355, 341, 187, and 361, respectively;
(lv) SEQ ID NOs: 95, 349, 356, 341, 187, and 362, respectively;
(lvi) SEQ ID NOs: 95, 119, 356, 341, 359, and 362, respectively;
(lvii) SEQ ID NOs: 346, 119, 356, 341, 359, and 362, respectively;
(lviii) SEQ ID NOs: 95, 350, 356, 341, 359, and 362, respectively;
(lix) SEQ ID NOs: 95, 351, 356, 341, 359, and 362, respectively;
(lx) SEQ ID NOs: 347, 119, 356, 341, 359, and 362, respectively;
(lxi) SEQ ID NOs: 346, 119, 356, 341, 359, and 362, respectively;
(lxii) SEQ ID NOs: 95, 119, 356, 341, 187, and 362, respectively;
(lxiii) SEQ ID NOs: 95, 352, 356, 341, 187, and 362, respectively;
(lxiv) SEQ ID NOs: 95, 350, 356, 341, 359, and 362, respectively;
(lxv) SEQ ID NOs: 95, 353, 356, 341, 359, and 362, respectively;
(lxvi) SEQ ID NOs: 95, 351, 356, 341, 359, and 362, respectively;
(lxvii) SEQ ID NOs: 95, 350, 356, 341, 359, and 362, respectively;
(lxviii) SEQ ID NOs: 346, 354, 356, 341, 359, and 363, respectively;
(lxix) SEQ ID NOs: 346, 348, 356, 357, 359, and 362, respectively;
(lxx) SEQ ID NOs: 346, 354, 356, 358, 187, and 362, respectively;
(lxxi) SEQ ID NOs: 95, 348, 151, 181, 187, and 208, respectively;
(lxxii) SEQ ID NOs: 90, 364, 373, 376, 388, and 231, respectively;
(lxxiii) SEQ ID NOs: 90, 364, 155, 377, 203, and 231, respectively;
(lxxiv) SEQ ID NOs: 90, 364, 374, 378, 203, and 231, respectively;
(lxxv) SEQ ID NOs: 90, 365, 155, 376, 203, and 392, respectively;
(lxxvi) SEQ ID NOs: 90, 364, 155, 376, 389, and 231, respectively;
(lxxvii) SEQ ID NOs: 90, 364, 155, 379, 203, and 231, respectively;
(lxxviii) SEQ ID NOs: 90, 366, 155, 380, 203, and 231, respectively;
(lxxix) SEQ ID NOs: 90, 364, 373, 381, 203, and 231, respectively;
(lxxx) SEQ ID NOs: 90, 367, 155, 382, 203, and 231, respectively;
(lxxxi) SEQ ID NOs: 90, 368, 155, 383, 203, and 231, respectively;
(lxxxii) SEQ ID NOs: 90, 364, 374, 384, 203, and 231, respectively;
(lxxxiii) SEQ ID NOs: 90, 368, 155, 376, 203, and 293, respectively;
(lxxxiv) SEQ ID NOs: 90, 364, 155, 378, 203, and 231, respectively;
(lxxxv) SEQ ID NOs: 90, 368, 155, 376, 203, and 231, respectively;
(lxxxvi) SEQ ID NOs: 90, 369, 155, 378, 203, and 394, respectively;
(lxxxvii) SEQ ID NOs: 90, 364, 155, 378, 203, and 231, respectively;
(lxxxviii) SEQ ID NOs: 90, 370, 155, 378, 203, and 394, respectively;
(lxxxix) SEQ ID NOs: 90, 371, 155, 378, 203, and 394, respectively;
(xc) SEQ ID NOs: 90, 368, 155, 385, 203, and 394, respectively;
(xci) SEQ ID NOs: 90, 368, 155, 378, 203, and 395, respectively;
(xcii) SEQ ID NOs: 90, 368, 155, 378, 390, and 394, respectively;
(xciii) SEQ ID NOs: 90, 372, 155, 378, 391, and 394, respectively;
(xciv) SEQ ID NOs: 90, 368, 375, 386, 203, and 394, respectively; or
(xcv) SEQ ID NOs: 90, 368, 155, 387, 203, and 394, respectively.

2. The antibody of claim 1 , wherein the antibody comprises a heavy chain variable region and a light chain variable region comprising the amino acid sequences of SEQ ID NOs:5 and 40, respectively; SEQ ID NOs:6 and 41, respectively; SEQ ID NOs:7 and 42, respectively; SEQ ID NOs:8 and 43, respectively; SEQ ID NOs:9 and 44, respectively; SEQ ID NOs:10 and 45, respectively; SEQ ID NOs:11 and 46, respectively; SEQ ID NOs:12 and 47, respectively; SEQ ID NOs:13 and 48, respectively; SEQ ID NOs:14 and 49, respectively; SEQ ID NOs:15 and 50, respectively; SEQ ID NOs:16 and 51, respectively; SEQ ID NOs:17 and 52, respectively; SEQ ID NOs:18 and 53, respectively; SEQ ID NOs:19 and 54, respectively; SEQ ID NOs:20 and 55, respectively; SEQ ID NOs:21 and 56, respectively; SEQ ID NOs:22 and 57, respectively; SEQ ID NOs:23 and 58, respectively; SEQ ID NOs:24 and 59, respectively; SEQ ID NOs:25 and 60, respectively; SEQ ID NOs:26 and 61, respectively; SEQ ID NOs:27 and 62, respectively; SEQ ID NOs:28 and 63, respectively; SEQ ID NOs:29 and 64, respectively; SEQ ID NOs:30 and 65, respectively; SEQ ID NOs:31 and 66, respectively; SEQ ID NOs:32 and 67, respectively; SEQ ID NOs:33 and 68, respectively; SEQ ID NOs:34 and 69, respectively; SEQ ID NOs:35 and 70, respectively; SEQ ID NOs:36 and 71, respectively

Assignees

• Alector Llc

Inventors

• Lee Seung-Joo
• Liang Spencer
• Yee Angie
• Roell Marina
• Rosenthal Arnon

Classifications

• C07K16/40 Primary

  against enzymes · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07K16/2818

  against CD28 or CD152 · CPC title

• C07K16/2827

  against B7 molecules, e.g. CD80, CD86 · CPC title

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title